Markets

Market

News Details

(22/05/2026 15:10)

Sun Pharmaceutical Q4 net profit down 69.57% at Rs 608.70 cr

The company reported standalone net profit of Rs 608.70 crore for the quarter ended March 31, 2026 as compared to Rs 2000.46 crore in the same period last year, registering a year-on-year decline of 69.57 per cent.

Net revenue of the company declined substantially by 31.23 per cent at Rs 4,887.27 crore in January-March quarter of this fiscal as against Rs 7,107.14 crore in the corresponding period last year.

During January-March quarter, operating expenses dropped by 14.33 per cent to Rs 3,594.91 crore from Rs 4,196.28 crore in year ago period.

Other Income dipped by 52.33 per cent at Rs 62.93 crore versus (Mar'25 Rs 132.00 crore).

Operating Profit slipped by 55.54 per cent to Rs 1,328.97 crore as against Rs 2,989.46 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 35.35 per cent in March quarter.

Interest declined by 0.23 per cent y-o-y to Rs 216.92 crore, while Taxation decreased by 64.84 per cent at Rs 215.02 crore (Mar'25 Rs 611.62 crore).

Prevent Unauthorized Transactions in your demat account -> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL on the same day....................issued in the interest of investors.
KYC is one-time exercise while dealing in securities markets -> Once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.